Spots Global Cancer Trial Database for the Safety and Efficacy of SENL103 Autologous T Cell Injection

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: the Safety and Efficacy of SENL103 Autologous T Cell Injection

Official Title: Clinical Study on the Safety and Efficacy of SENL103 Autologous T Cell Injection in the Treatment of Recurrent or Refractory Plasma Cell Blood Tumors

Study ID: NCT06067581

Conditions

Multiple Myeloma

Interventions

SENL103

Study Description

Brief Summary: To observe the safety and efficacy of SENL103 cells in the treatment of patients with recurrent or refractory plasma cell blood tumors.

Detailed Description: Primary endpoint To observe the number and incidence of adverse events after intravenous infusion of SENL103. To evaluate possible adverse reactions recorded within 1 month after SENL103 infusion, including the number, incidence and severity of symptoms such as cytokine release syndrome and neurotoxic reactions; Secondary endpoints 1. Efficacy indicators: The efficacy after cell retransfusion was observed by strict complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), stable disease (SD), and progression-free survival (PFS rate); 2. PK index: the highest concentration of SENL103 cells amplified in peripheral blood (Cmax, measured by flow cytometry and qPCR), the time to reach the highest concentration (Tmax) and the duration of cell survival in the patient; 3. PD index: proportion of peripheral blood plasma cells, concentration of free BCMA and cytokine release at each time point; 4. Quality of life assessment: the changes of subjects' quality of life before and after treatment were observed.